BTIG Research Lowers Progyny (NASDAQ:PGNY) Price Target to $30.00

Progyny (NASDAQ:PGNY) had its price objective reduced by research analysts at BTIG Research from $35.00 to $30.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 63.84% from the company’s previous close.

Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a research report on Wednesday, January 21st. KeyCorp cut their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Citigroup upgraded shares of Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Truist Financial cut their price target on shares of Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Monday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Progyny Stock Performance

Shares of PGNY opened at $18.31 on Thursday. The firm’s 50-day simple moving average is $23.09 and its two-hundred day simple moving average is $22.92. Progyny has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The stock has a market cap of $1.50 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter last year, the company earned $0.42 EPS. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts predict that Progyny will post 0.6 EPS for the current year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 7,455 shares of company stock valued at $129,515 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently made changes to their positions in PGNY. California State Teachers Retirement System boosted its holdings in shares of Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after buying an additional 457 shares during the last quarter. Teza Capital Management LLC increased its stake in shares of Progyny by 5.4% in the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares in the last quarter. Leibman Financial Services Inc. lifted its position in Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after purchasing an additional 528 shares in the last quarter. Aristides Capital LLC raised its stake in shares of Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after buying an additional 528 shares during the period. Finally, Oxford Asset Management LLP increased its holdings in Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after acquiring an additional 531 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.